Ultragenyx Pharmaceutical
RARE
#4141
Rank
C$4.29 B
Marketcap
C$43.65
Share price
5.20%
Change (1 day)
-12.25%
Change (1 year)

Earnings for Ultragenyx Pharmaceutical (RARE)

Earnings in 2026 (TTM): -C$0.75 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current earnings are C$0.66 Billion. In 2025 the company made an earning of -C$0.73 Billion a decrease over its 2024 earnings that were of -C$0.72 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Ultragenyx Pharmaceutical from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -C$0.75 Billion2.52%
2025 -C$0.73 Billion1%
2024 -C$0.72 Billion-6.99%
2023 -C$0.77 Billion-17.65%
2022 -C$0.94 Billion55.52%
2021 -C$0.61 Billion178.53%
2020 -C$0.22 Billion-59.64%
2019 -C$0.54 Billion1.46%
2018 -C$0.53 Billion12.9%
2017 -C$0.47 Billion32.63%
2016 -C$0.36 Billion67.87%
2015 -C$0.21 Billion160.2%
2014 -C$80.55 Million66.64%
2013 -C$48.34 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Lexicon Pharmaceuticals
LXRX
-C$97.29 Million-87.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
-C$38.93 Million-94.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
C$0.27 M-100.04%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
C$0.54 B-171.86%๐Ÿ‡บ๐Ÿ‡ธ USA